All the previous findings support the diagnosis of acute onset LHON. Discussion of a new and promising treatment was discussed in detail. I recommended that the patient take the first plane the next morning to Los Angeles for possible treatment with Edison Pharmaceutical’s new drug EPI 743. All the data, including the previous genetic confirmation of LHON mt 11778 was shared with the group at Doheney Eye Institute, USC, Keck School of Medicine. Within a week, treatment was initiated once the FDA approval was obtained. Favorable results in 5 other patients with LHON has led to an FDA clinical trial that will begin in July 2011.1